Skip to content

Study · Systematic review · 2026

18 results

GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety.

Soliman AT, Alyafei F, Khalil A, Kardousha AT, Ahmed S, Alaaraj N, Hamed N

Diabetes research and clinical practice28 Jun 2026

PMID42365860 (opens in a new tab)DOI10.1016/j.diabres.2026.113400 (opens in a new tab)PepBankPUB-42365860
Publisher pagePubMedAsk about this study
Jump to 18 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study18

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In the systematic review of pediatric studies, semaglutide 2.4 mg/week had the greatest reported BMI reduction in adolescents with obesity.

    In plain wordsIn reviewed adolescent obesity studies, semaglutide had the greatest reported BMI reduction.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody mass index
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg/weekAs given in this study (human).

    Source sentences

    Summary
    Semaglutide 2.4 mg/week produced the greatest BMI reduction in adolescents with obesity, followed by liraglutide 3.0 mg/day, which also improved BMI SDS in adolescents and younger children.
    2 context sentences
    Summary · context
    This review systematically evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity or T2DM.
    Summary · context
    PubMed-indexed studies published from 2000 to 2025 were reviewed, including seven pivotal randomized controlled trials and six meta-analyses involving 901 participants aged 6 to < 18 years.
  2. 02HumanSystematic reviewEfficacy outcome

    In adolescents and younger children with obesity, liraglutide 3.0 mg/day improved BMI standard deviation score in the systematic review.

    In plain wordsIn adolescents and younger children with obesity, liraglutide improved BMI standard deviation score.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedBMI standard deviation score
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg/dayAs given in this study (human).

    Source sentences

    Summary
    Semaglutide 2.4 mg/week produced the greatest BMI reduction in adolescents with obesity, followed by liraglutide 3.0 mg/day, which also improved BMI SDS in adolescents and younger children.
    2 context sentences
    Summary · context
    This review systematically evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity or T2DM.
    Summary · context
    PubMed-indexed studies published from 2000 to 2025 were reviewed, including seven pivotal randomized controlled trials and six meta-analyses involving 901 participants aged 6 to < 18 years.
  3. 03HumanSystematic reviewEfficacy outcome

    In youth-onset type 2 diabetes, liraglutide 1.8 mg/day improved HbA1c compared with placebo.

    In plain wordsIn youth with type 2 diabetes, liraglutide improved HbA1c more than placebo.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedHbA1c
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/dayAs given in this study (human).

    Source sentences

    Summary
    In youth-onset T2DM, liraglutide 1.8 mg/day and dulaglutide significantly improved HbA1c compared with placebo.
    2 context sentences
    Summary · context
    This review systematically evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity or T2DM.
    Summary · context
    PubMed-indexed studies published from 2000 to 2025 were reviewed, including seven pivotal randomized controlled trials and six meta-analyses involving 901 participants aged 6 to < 18 years.
  4. 04HumanSystematic reviewEfficacy outcome

    In the systematic review of adolescents with obesity, liraglutide 3.0 mg/day ranked after semaglutide 2.4 mg/week for reported BMI reduction; no head-to-head estimate was provided.

    In plain wordsIn reviewed adolescent obesity studies, liraglutide ranked after semaglutide for BMI reduction.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody mass index
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg/dayAs given in this study (human).

    Source sentences

    Summary
    Semaglutide 2.4 mg/week produced the greatest BMI reduction in adolescents with obesity, followed by liraglutide 3.0 mg/day, which also improved BMI SDS in adolescents and younger children.
    2 context sentences
    Summary · context
    This review systematically evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity or T2DM.
    Summary · context
    PubMed-indexed studies published from 2000 to 2025 were reviewed, including seven pivotal randomized controlled trials and six meta-analyses involving 901 participants aged 6 to < 18 years.

Studies that did not test the peptide alone14

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In the systematic review of youth with obesity or T2D, pooled weight-reducing agents including semaglutide improved insulin resistance.

    In plain wordsIn youth with obesity or T2D, pooled weight-loss drugs including semaglutide improved insulin resistance.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedInsulin resistance
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Weight-reducing agents also improved insulin resistance and modestly reduced triglycerides, while LDL-cholesterol changes were minimal.
    3 context sentences
    Summary · context
    This review systematically evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity or T2DM.
    Summary · context
    PubMed-indexed studies published from 2000 to 2025 were reviewed, including seven pivotal randomized controlled trials and six meta-analyses involving 901 participants aged 6 to < 18 years.
    Summary · context
    Semaglutide 2.4 mg/week produced the greatest BMI reduction in adolescents with obesity, followed by liraglutide 3.0 mg/day, which also improved BMI SDS in adolescents and younger children.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In the systematic review of youth with obesity or T2D, pooled weight-reducing agents including liraglutide improved insulin resistance.

    In plain wordsIn youth with obesity or T2D, pooled weight-loss drugs including liraglutide improved insulin resistance.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedInsulin resistance
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Weight-reducing agents also improved insulin resistance and modestly reduced triglycerides, while LDL-cholesterol changes were minimal.
    3 context sentences
    Summary · context
    This review systematically evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity or T2DM.
    Summary · context
    PubMed-indexed studies published from 2000 to 2025 were reviewed, including seven pivotal randomized controlled trials and six meta-analyses involving 901 participants aged 6 to < 18 years.
    Summary · context
    Semaglutide 2.4 mg/week produced the greatest BMI reduction in adolescents with obesity, followed by liraglutide 3.0 mg/day, which also improved BMI SDS in adolescents and younger children.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 07HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In the systematic review of youth with obesity or T2D, pooled weight-reducing agents including semaglutide modestly reduced triglycerides.

    In plain wordsIn youth with obesity or T2D, pooled weight-loss drugs including semaglutide modestly lowered triglycerides.

    Peptide
    Semaglutide
    Outcome
    DecreaseTriglycerides
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    Weight-reducing agents also improved insulin resistance and modestly reduced triglycerides, while LDL-cholesterol changes were minimal.
    3 context sentences
    Summary · context
    This review systematically evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity or T2DM.
    Summary · context
    PubMed-indexed studies published from 2000 to 2025 were reviewed, including seven pivotal randomized controlled trials and six meta-analyses involving 901 participants aged 6 to < 18 years.
    Summary · context
    Semaglutide 2.4 mg/week produced the greatest BMI reduction in adolescents with obesity, followed by liraglutide 3.0 mg/day, which also improved BMI SDS in adolescents and younger children.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 08HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In the systematic review of youth with obesity or T2D, pooled weight-reducing agents including liraglutide modestly reduced triglycerides.

    In plain wordsIn youth with obesity or T2D, pooled weight-loss drugs including liraglutide modestly lowered triglycerides.

    Peptide
    Liraglutide
    Outcome
    DecreaseTriglycerides
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    Weight-reducing agents also improved insulin resistance and modestly reduced triglycerides, while LDL-cholesterol changes were minimal.
    3 context sentences
    Summary · context
    This review systematically evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity or T2DM.
    Summary · context
    PubMed-indexed studies published from 2000 to 2025 were reviewed, including seven pivotal randomized controlled trials and six meta-analyses involving 901 participants aged 6 to < 18 years.
    Summary · context
    Semaglutide 2.4 mg/week produced the greatest BMI reduction in adolescents with obesity, followed by liraglutide 3.0 mg/day, which also improved BMI SDS in adolescents and younger children.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 09HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In the systematic review of youth with obesity or T2D, pooled weight-reducing agents including semaglutide showed minimal LDL-cholesterol changes.

    In plain wordsIn youth with obesity or T2D, pooled weight-loss drugs including semaglutide showed little LDL-cholesterol change.

    Peptide
    Semaglutide
    Outcome
    Not applicableLDL-cholesterol
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    Weight-reducing agents also improved insulin resistance and modestly reduced triglycerides, while LDL-cholesterol changes were minimal.
    3 context sentences
    Summary · context
    This review systematically evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity or T2DM.
    Summary · context
    PubMed-indexed studies published from 2000 to 2025 were reviewed, including seven pivotal randomized controlled trials and six meta-analyses involving 901 participants aged 6 to < 18 years.
    Summary · context
    Semaglutide 2.4 mg/week produced the greatest BMI reduction in adolescents with obesity, followed by liraglutide 3.0 mg/day, which also improved BMI SDS in adolescents and younger children.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  6. 10HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In the systematic review of youth with obesity or T2D, pooled weight-reducing agents including liraglutide showed minimal LDL-cholesterol changes.

    In plain wordsIn youth with obesity or T2D, pooled weight-loss drugs including liraglutide showed little LDL-cholesterol change.

    Peptide
    Liraglutide
    Outcome
    Not applicableLDL-cholesterol
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    Weight-reducing agents also improved insulin resistance and modestly reduced triglycerides, while LDL-cholesterol changes were minimal.
    3 context sentences
    Summary · context
    This review systematically evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity or T2DM.
    Summary · context
    PubMed-indexed studies published from 2000 to 2025 were reviewed, including seven pivotal randomized controlled trials and six meta-analyses involving 901 participants aged 6 to < 18 years.
    Summary · context
    Semaglutide 2.4 mg/week produced the greatest BMI reduction in adolescents with obesity, followed by liraglutide 3.0 mg/day, which also improved BMI SDS in adolescents and younger children.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  7. 11HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In youth with obesity or T2D, nausea was among the most frequent adverse events across GLP-1 drugs including semaglutide; gastrointestinal events were generally transient and dose dependent.

    In plain wordsIn youth with obesity or T2D, nausea was common across GLP-1 drugs including semaglutide; gastrointestinal events were generally transient and dose dependent.

    Peptide
    Semaglutide
    Outcome
    Not applicableNausea
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Gastrointestinal adverse events, mainly nausea and vomiting, were the most frequent and were generally transient and dose dependent.
    3 context sentences
    Summary · context
    This review systematically evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity or T2DM.
    Summary · context
    PubMed-indexed studies published from 2000 to 2025 were reviewed, including seven pivotal randomized controlled trials and six meta-analyses involving 901 participants aged 6 to < 18 years.
    Summary · context
    Semaglutide 2.4 mg/week produced the greatest BMI reduction in adolescents with obesity, followed by liraglutide 3.0 mg/day, which also improved BMI SDS in adolescents and younger children.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  8. 12HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In youth with obesity or T2D, vomiting was among the most frequent adverse events across GLP-1 drugs including semaglutide; gastrointestinal events were generally transient and dose dependent.

    In plain wordsIn youth with obesity or T2D, vomiting was common across GLP-1 drugs including semaglutide; gastrointestinal events were generally transient and dose dependent.

    Peptide
    Semaglutide
    Outcome
    Not applicableVomiting
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Gastrointestinal adverse events, mainly nausea and vomiting, were the most frequent and were generally transient and dose dependent.
    3 context sentences
    Summary · context
    This review systematically evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity or T2DM.
    Summary · context
    PubMed-indexed studies published from 2000 to 2025 were reviewed, including seven pivotal randomized controlled trials and six meta-analyses involving 901 participants aged 6 to < 18 years.
    Summary · context
    Semaglutide 2.4 mg/week produced the greatest BMI reduction in adolescents with obesity, followed by liraglutide 3.0 mg/day, which also improved BMI SDS in adolescents and younger children.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  9. 13HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In youth with obesity or T2D, nausea was among the most frequent adverse events across GLP-1 drugs including liraglutide; gastrointestinal events were generally transient and dose dependent.

    In plain wordsIn youth with obesity or T2D, nausea was common across GLP-1 drugs including liraglutide; gastrointestinal events were generally transient and dose dependent.

    Peptide
    Liraglutide
    Outcome
    Not applicableNausea
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Gastrointestinal adverse events, mainly nausea and vomiting, were the most frequent and were generally transient and dose dependent.
    3 context sentences
    Summary · context
    This review systematically evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity or T2DM.
    Summary · context
    PubMed-indexed studies published from 2000 to 2025 were reviewed, including seven pivotal randomized controlled trials and six meta-analyses involving 901 participants aged 6 to < 18 years.
    Summary · context
    Semaglutide 2.4 mg/week produced the greatest BMI reduction in adolescents with obesity, followed by liraglutide 3.0 mg/day, which also improved BMI SDS in adolescents and younger children.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  10. 14HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In youth with obesity or T2D, vomiting was among the most frequent adverse events across GLP-1 drugs including liraglutide; gastrointestinal events were generally transient and dose dependent.

    In plain wordsIn youth with obesity or T2D, vomiting was common across GLP-1 drugs including liraglutide; gastrointestinal events were generally transient and dose dependent.

    Peptide
    Liraglutide
    Outcome
    Not applicableVomiting
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Gastrointestinal adverse events, mainly nausea and vomiting, were the most frequent and were generally transient and dose dependent.
    3 context sentences
    Summary · context
    This review systematically evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity or T2DM.
    Summary · context
    PubMed-indexed studies published from 2000 to 2025 were reviewed, including seven pivotal randomized controlled trials and six meta-analyses involving 901 participants aged 6 to < 18 years.
    Summary · context
    Semaglutide 2.4 mg/week produced the greatest BMI reduction in adolescents with obesity, followed by liraglutide 3.0 mg/day, which also improved BMI SDS in adolescents and younger children.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  11. 15HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In the systematic review of youth with obesity or T2D, no significant adverse effects on linear growth were reported across GLP-1 drugs including semaglutide.

    In plain wordsIn youth with obesity or T2D, no significant adverse effect on linear growth was reported across GLP-1 drugs including semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableLinear growth
    Study

    n: not reported in source

    Outcome group
    Adverse events · Endocrine and hormones

    Source sentences

    Summary
    No significant adverse effects on linear growth or pubertal progression were reported.
    3 context sentences
    Summary · context
    This review systematically evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity or T2DM.
    Summary · context
    PubMed-indexed studies published from 2000 to 2025 were reviewed, including seven pivotal randomized controlled trials and six meta-analyses involving 901 participants aged 6 to < 18 years.
    Summary · context
    Semaglutide 2.4 mg/week produced the greatest BMI reduction in adolescents with obesity, followed by liraglutide 3.0 mg/day, which also improved BMI SDS in adolescents and younger children.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  12. 16HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In the systematic review of youth with obesity or T2D, no significant adverse effects on pubertal progression were reported across GLP-1 drugs including semaglutide.

    In plain wordsIn youth with obesity or T2D, no significant adverse effect on puberty was reported across GLP-1 drugs including semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicablePubertal progression
    Study

    n: not reported in source

    Outcome group
    Adverse events · Endocrine and hormones

    Source sentences

    Summary
    No significant adverse effects on linear growth or pubertal progression were reported.
    3 context sentences
    Summary · context
    This review systematically evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity or T2DM.
    Summary · context
    PubMed-indexed studies published from 2000 to 2025 were reviewed, including seven pivotal randomized controlled trials and six meta-analyses involving 901 participants aged 6 to < 18 years.
    Summary · context
    Semaglutide 2.4 mg/week produced the greatest BMI reduction in adolescents with obesity, followed by liraglutide 3.0 mg/day, which also improved BMI SDS in adolescents and younger children.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  13. 17HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In the systematic review of youth with obesity or T2D, no significant adverse effects on linear growth were reported across GLP-1 drugs including liraglutide.

    In plain wordsIn youth with obesity or T2D, no significant adverse effect on linear growth was reported across GLP-1 drugs including liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableLinear growth
    Study

    n: not reported in source

    Outcome group
    Adverse events · Endocrine and hormones

    Source sentences

    Summary
    No significant adverse effects on linear growth or pubertal progression were reported.
    3 context sentences
    Summary · context
    This review systematically evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity or T2DM.
    Summary · context
    PubMed-indexed studies published from 2000 to 2025 were reviewed, including seven pivotal randomized controlled trials and six meta-analyses involving 901 participants aged 6 to < 18 years.
    Summary · context
    Semaglutide 2.4 mg/week produced the greatest BMI reduction in adolescents with obesity, followed by liraglutide 3.0 mg/day, which also improved BMI SDS in adolescents and younger children.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  14. 18HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In the systematic review of youth with obesity or T2D, no significant adverse effects on pubertal progression were reported across GLP-1 drugs including liraglutide.

    In plain wordsIn youth with obesity or T2D, no significant adverse effect on puberty was reported across GLP-1 drugs including liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicablePubertal progression
    Study

    n: not reported in source

    Outcome group
    Adverse events · Endocrine and hormones

    Source sentences

    Summary
    No significant adverse effects on linear growth or pubertal progression were reported.
    3 context sentences
    Summary · context
    This review systematically evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity or T2DM.
    Summary · context
    PubMed-indexed studies published from 2000 to 2025 were reviewed, including seven pivotal randomized controlled trials and six meta-analyses involving 901 participants aged 6 to < 18 years.
    Summary · context
    Semaglutide 2.4 mg/week produced the greatest BMI reduction in adolescents with obesity, followed by liraglutide 3.0 mg/day, which also improved BMI SDS in adolescents and younger children.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.